Menu
 

Search abstracts


Maximum doses of proton pump inhibitors in hepatic impairment

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty)
  • Co-author(s): Andreia Primo: Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal
    Inês Martins: Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal
    Luís Caetano: Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal
    Nuno Pereira: Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal
    Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
    Manuel Morgado: Higher School of Health, Portuguese Pharmaceutical Society, Guarda, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal;Pharmaceutical Services, Hospital Centre of Cova da Beira, Covilhã, Portugal
  • Abstract:

    Background

    Some of the most commonly used drugs, including most proton pump inhibitors (PPIs) are eliminated by the hepatic route. If liver function is impaired, it can be anticipated that hepatic clearance will be delayed, which can lead to more pronounced drug accumulation.

    Methods

    The databases of the Nacional Authority of Medicines and Health

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses